Document Detail

Short-term antihypertensive efficacy of perindopril according to clinical profile of 3,188 patients: A meta-analysis.
MedLine Citation:
PMID:  20535716     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Perindopril, a long-acting angiotensin converting enzyme-inhibitor, reduces incidence of cardiovascular end points in a wide range of patients. This effect depends on both the antihypertensive and blood pressure lowering unrelated effects. The aim of the study was to check the possible influence of patients' clinical profile on the antihypertensive efficacy of perindopril. METHODS: A meta-analysis of individual data of hypertensive patients enrolled in five open studies tested the efficacy and safety of perindopril over a 12-week treatment period. RESULTS: We included data of 3,188 men (39%) and women, aged on average 53 years, whose baseline systolic/diastolic blood pressure averaged 163/99 mm Hg and on average declined by 27/17 mm Hg. Mean duration of hypertension was five years, and 34% of patients had prior cardiovascular complications. We found no difference in the antihypertensive effect of perindopril in patients with complicated vs non-complicated hypertension (DSBP 0.05, 95%CI: -1.5 to 1.6 mm Hg, p = 0.95), in older vs younger patients (DSBP 2.4, 95%CI: -3.2 to 7.9 mm Hg, p = 0.41), in men vs women (DSBP -1.43, 95%CI: -3.4 to 0.5, p = 0.15), and in patients with long-lasting vs shorter duration of hypertension (DSBP 0.0, 95%CI: -1.0 to 1.0 mm Hg, p = 1.0). The antihypertensive effect of perindopril was stronger in patients with greater (> or = 160 mm Hg) systolic blood pressure (DSBP 12.3, 95%CI: 5.5 to 19.0, p = 0.0004). The effect on diastolic blood pressure tended to be greater in younger patients (DDBP -0.63, 95%CI: -1.2 to -0.02 mm Hg, p = 0.04). CONCLUSIONS: Perindopril is an effective antihypertensive medication. Seems not to be adversely affected by the clinical profile of the patient.
Jerzy Gasowski; Arleta Wilkins; Józef Drzewoski; Jadwiga Kłoś; Zbigniew Gaciong; Marek Kabat; Tomasz Grodzicki
Related Documents :
2455106 - Verapamil and prazosin in essential hypertension: evidence of a synergistic combination?
11773986 - Blood pressure levels, risk factors and antihypertensive treatments: lessons from the s...
20626346 - Why and how we should treat elderly patients with hypertension?
23982026 - Effects of propofol on patient-ventilator synchrony and interaction during pressure sup...
686186 - Preferential distribution of inhbititory cardiac receptors in left ventricle of the dog.
5938826 - Interactions of oxygen at high pressure and radiation in drosophila.
Publication Detail:
Type:  Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cardiology journal     Volume:  17     ISSN:  1897-5593     ISO Abbreviation:  Cardiol J     Publication Date:  2010  
Date Detail:
Created Date:  2010-06-10     Completed Date:  2010-09-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101392712     Medline TA:  Cardiol J     Country:  Poland    
Other Details:
Languages:  eng     Pagination:  259-66     Citation Subset:  IM    
Department of Gerontology and Internal Medicine, Jagiellonian University, Kraków, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin-Converting Enzyme Inhibitors / adverse effects,  therapeutic use*
Antihypertensive Agents / adverse effects,  therapeutic use*
Blood Pressure / drug effects*
Clinical Trials as Topic
Hypertension / drug therapy*,  physiopathology
Middle Aged
Multicenter Studies as Topic
Perindopril / adverse effects,  therapeutic use*
Time Factors
Treatment Outcome
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 82834-16-0/Perindopril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Can opium abuse be a risk factor for carotid stenosis in patients who are candidates for coronary ar...
Next Document:  Physicians' knowledge and attitudes regarding implantable cardioverter-defibrillators.